InFlectis BioScience strengthens its intellectual property position in Europe and in the USA

InFlectis BioScience strengthens its intellectual property position in Europe and in the USA

InFlectis BioScience SAS, a biopharmaceutical company specializing in the discovery and development of drugs to treat orphan and non-orphan protein conformational disorders, today announced the strengthening of its intellectual property portfolio in Europe and in the USA with the issuance of two patents entitled “Benzylideneguanidine derivatives and therapeutic use for the treatment of protein misfolding diseases“.

Further informations in the Press Release